PURPOSE: P-glycoprotein limits the tissue penetration of many antiretroviral drugs. The aim of our study was to characterize the effects of the P-glycoprotein substrate cyclosporin A on T cell P-glycoprotein activity in human immunodeficiency virus-infected participants in the AIDS Clinical Trials Group study A5138. METHODS: We studied P-glycoprotein activity on CD4 and CD8 T cells in 16 participants randomized to receiveoral cyclosporin A (n=9) or not (n=7) during initiation antiretroviral therapy (ART) that did not include protease or non-nucleoside reverse transcriptase inhibitors. RESULTS:CD4 T cell P-glycoprotein activity decreased by a median of 8 percentage points with cyclosporin A/ART (difference between cyclosporin A/ART vs. ART only, P= 0.001). Plasma trough cyclosporin A concentrations correlated with the change in P-glycoprotein activity in several T cell subsets. CONCLUSIONS:Oral cyclosporin A can inhibit peripheral blood CD4 T cell P-glycoprotein activity. Targeted P-glycoprotein inhibition may enhance the delivery of ART to T cells.
RCT Entities:
PURPOSE:P-glycoprotein limits the tissue penetration of many antiretroviral drugs. The aim of our study was to characterize the effects of the P-glycoprotein substrate cyclosporin A on T cell P-glycoprotein activity in humanimmunodeficiency virus-infectedparticipants in the AIDS Clinical Trials Group study A5138. METHODS: We studied P-glycoprotein activity on CD4 and CD8 T cells in 16 participants randomized to receive oral cyclosporin A (n=9) or not (n=7) during initiation antiretroviral therapy (ART) that did not include protease or non-nucleoside reverse transcriptase inhibitors. RESULTS:CD4 T cell P-glycoprotein activity decreased by a median of 8 percentage points with cyclosporin A/ART (difference between cyclosporin A/ART vs. ART only, P= 0.001). Plasma trough cyclosporin A concentrations correlated with the change in P-glycoprotein activity in several T cell subsets. CONCLUSIONS: Oral cyclosporin A can inhibit peripheral blood CD4 T cell P-glycoprotein activity. Targeted P-glycoprotein inhibition may enhance the delivery of ART to T cells.
Authors: David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Leena Gandhi; Matthew W Harding; Marcus Neubauer; Corey J Langer; Melvin Moore; Helen J Ross; Bruce E Johnson; Thomas J Lynch Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Todd Hulgan; John P Donahue; Charlene Hawkins; Derya Unutmaz; Richard T D'Aquila; Stephen Raffanti; Fred Nicotera; Peter Rebeiro; Husamettin Erdem; Melissa Rueff; David W Haas Journal: J Acquir Immune Defic Syndr Date: 2003-10-01 Impact factor: 3.731
Authors: Becky Chandler; Lisa Almond; Jennifer Ford; Andrew Owen; Patrick Hoggard; Saye Khoo; David Back Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731
Authors: Abhilash K Ravindranath; Swayamjot Kaur; Roman P Wernyj; Muthu N Kumaran; Karl E Miletti-Gonzalez; Rigel Chan; Elaine Lim; Kiran Madura; Lorna Rodriguez-Rodriguez Journal: Oncotarget Date: 2015-09-22